Randomized trial evaluates miRNA detection in cancer diagnosis, indicating cost-effective monitoring potential.
Key Points
This study aims to develop a sensitive and specific platform for detecting microRNAs in liquid biopsies to enhance cancer diagnosis and treatment monitoring.
Developed the SCAN platform integrating split CRISPR/Cas12a with catalytic hairpin assembly.
Achieved a detection limit of 2 fM for miR-21 using a label-free G4/NMM reporter.
Tested the platform on various cancer cell lines and patient plasma samples.
Detected miR-21 with a sensitivity approximately 5 orders of magnitude higher than standard methods.
Differentiated cancer patient plasma samples from healthy individuals with high specificity.
Tracked treatment responses in noninvasive urine analyses for prostate and bladder cancers.